Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) EV-to-EBIT : -0.07 (As of May. 24, 2024)

Advanced Proteome Therapeutics EV-to-EBIT Chart

Advanced Proteome Therapeutics Annual Data
	Trend	Jul13	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22
EV-to-EBIT		Get a 7-Day Free Trial					-6.30	-2.02	-1.03	-4.38	3.94

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
EV-to-EBIT	Get a 7-Day Free Trial															4.00	3.94	-0.10	0.14	-0.21

Competitive Comparison of Advanced Proteome Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Advanced Proteome Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Proteome Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's EV-to-EBIT falls into.

Advanced Proteome Therapeutics EV-to-EBIT Calculation

Advanced Proteome Therapeutics's EV-to-EBIT for today is calculated as:

Advanced Proteome Therapeutics's current Enterprise Value is $0.14 Mil.
Advanced Proteome Therapeutics's EBIT for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics  (OTCPK:APTCF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Advanced Proteome Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2023 is calculated as:

Advanced Proteome Therapeutics's Enterprise Value for the quarter that ended in Apr. 2023 was $1.50 Mil.
Advanced Proteome Therapeutics's EBIT for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description